Akero Therapeutics Inc (AKRO) — Strategic Asset Allocation Index

Latest as of September 2025: 26.2%

Akero Therapeutics Inc (AKRO) has a Strategic Asset Allocation Index of 26.2% as of September 2025. Strategic assets (PP&E of $- plus long-term investments of $250.49 Million) total $250.49 Million, measured against net assets of $957.64 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.

SAAI

26.2%
Strategic Assets / Net Assets

Strategic Assets

$250.49 Million
PP&E + LT Investments

PP&E

$-
USD

Net Assets

$957.64 Million
USD

Akero Therapeutics Inc Strategic Asset Allocation Index (2020–2024)

This chart shows how Akero Therapeutics Inc's Strategic Asset Allocation Index has evolved across 5 annual periods from 2020 to 2024. As of September 2025, the index stands at 26.2%, representing strategic assets of $250.49 Million against net assets of $957.64 Million USD. Explore Akero Therapeutics Inc (AKRO) cash conversion ratio to assess how effectively this company generates cash.

Annual Strategic Asset Allocation Index for Akero Therapeutics Inc (2020–2024)

The table below presents the year-by-year Strategic Asset Allocation Index for Akero Therapeutics Inc from 2020 to 2024, covering 5 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see AKRO market cap overview.

Year SAAI Strategic Assets (USD) PP&E LT Investments Net Assets Change (pp)
2024 7.3% $54.75 Million $- $54.75 Million $750.11 Million ▲ +3.7 pp
2023 3.6% $19.28 Million $- $19.28 Million $535.31 Million ▲ +3.6 pp
2022 0.0% $47.00K $47.00K $0.00 $326.56 Million ▼ 0.0 pp
2021 0.1% $90.00K $90.00K $- $169.11 Million ▼ -0.6 pp
2020 0.7% $1.79 Million $1.79 Million $- $258.71 Million
pp = percentage points